

Special Issue

New Insights in Thoracic Sarcoma

Message from the Guest Editor

Sarcomas are rare cancers deriving from mesenchymal cells and include over one hundred different histologic entities. Sarcoma may involve any structure throughout the body. Despite their rarity, Surgeons, Medical or Radiation Oncologists, Radiologists and Respiriologists dealing with Thoracic Oncology will invariably encounter Thoracic Sarcomas as primary or secondary lesions. Primary thoracic sarcoma most commonly involve the chest wall, pleura, mediastinum and lung. Secondary lesions are most commonly seen in the pleura (pleural sarcomatosis) or in the pulmonary parenchyma. Awareness and identification of these rare entities as well as adequate diagnosis and treatment are of paramount importance for optimal outcome. This Special Issue aims to

- Describe the features and treatment of thoracic sarcomas based on their anatomic location: lung, pulmonary artery, mediastinum and chest wall.
- Discuss the potential of systemic treatment for thoracic sarcoma, applied locally (in-vivo lung perfusion-IVLP, Hyperthermic Intrathoracic Chemotherapy –HITOC).
- Discuss future systemic treatment beyond chemotherapy.

Guest Editor

Prof. Dr. Stéphane Collaud

Professor and Chair in Thoracic Surgery, Lung Clinic, Kliniken der Stadt Köln, University of Witten Herdecke, Cologne, Germany

Deadline for manuscript submissions

closed (30 September 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/154275

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)